INOVIO PHARMACEUTICALS, INC. — fact timeline

INOVIO PHARMACEUTICALS, INC.: Amendment to bylaws to clarify Chairman role, establish Lead Independent Director, and update order of presiding officers (effective 2026-05-19).

“On May 19, 2026, the board of directors (the “ Board ”) of Inovio Pharmaceuticals, Inc. (the “ Company ”) approved an amendment to the Company’s Amended and Restated bylaws (the “ Bylaws Amendment ”) effective immediately to further enhance the Company’s corporate governance practices by, among other things, (i) clarifying the role of the Chairman of the Board, including that the Chairman shall not be deemed an officer of the corporation unless expressly designated as such by the Board, (ii) establishing the position of Lead Independent Director, including the designation, duties and responsibilities thereof, and requiring the appointment of a Lead Independent Director in the event the Chief Executive Officer also serves as Chairman of the Board and (iii) updating the order of presiding officers at meetings of the Board and stockholders to reflect the foregoing changes.”

INOVIO PHARMACEUTICALS, INC. entered into Underwriting Agreement with Piper Sandler & Co. valued at Public offering of 12,500,000 shares of common stock and Series A and Series B warrants with an opti (effective 2026-04-02).

“On April 2, 2026, Inovio Pharmaceuticals, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Piper Sandler & Co., as representative of the several underwriters named therein (collectively, the “ Underwriters ”), relating to the issuance and sale by the Company in a public offering of 12,500,000 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), and accompanying Series A warrants to purchase up to 12,500,000 shares of its Common Stock (or pre-funded warrants, each representing the right to purchase one share of Common Stock at an exercise price of $0.001 (the “ Pre-Funded Warrants ”) in lieu thereof) at an exercise price of $1.40 per share of common stock (or $1.399 per Pre-Funded Warrant) (the “ Series A Warrants ”) and Series B warrants to purchase up to 12,500,000 shares of its Common Stock (or Pre-Funded Warrants in lieu thereof) at an exercise price of $1.40 per share of Common S”

INOVIO PHARMACEUTICALS, INC. amended Series A Warrants (effective 2026-01-27).

“On January 27, 2026, Inovio Pharmaceuticals, Inc. (the “Company”) amended each of its outstanding Series A warrants issued on July 7, 2025 (the “Series A Warrants”) to extend the expiration date”

INOVIO PHARMACEUTICALS, INC. reported financial results for first quarter of 2024.

“On May 13, 2024, Inovio Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended March 31, 2024.”

INOVIO PHARMACEUTICALS, INC. entered into Underwriting Agreement with Oppenheimer & Co. Inc. and Citizens JMP Securities, LLC, as representatives of the several underwriters named therein valued at approximately $33.2 million (effective 2024-04-15).

“On April 15, 2024, Inovio Pharmaceuticals, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Oppenheimer & Co. Inc. and Citizens JMP Securities, LLC, as representatives of the several underwriters named therein (collectively, the “ Underwriters ”), relating to the issuance and sale by the Company in an underwritten registered direct offering (the “ Offering ”) of 2,536,258 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), at a price of $7.693 per share and pre-funded warrants to purchase up to 2,135,477 shares of Common Stock (the “ Pre-Funded Warrants ”) at a price of $7.692 per Pre-Funded Warrant, which represents the per share price for the Shares less the $0.001 per share exercise price for each Pre-Funded Warrant.”